CAMP4 Therapeutics Corporation (CAMP) AI Stock Analysis

• Market Cap: $328.64M
• Dividend Yield: N/A
• Average Volume (3M): 1.59M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.98
• Revenue Growth: N/A
• EPS Growth: 5.51%
• Country: US
• Employees: 55
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.55
• Shares Outstanding: 46,881,134
• 10 Day Avg. Volume: 141,089
• 30 Day Avg. Volume: 1,592,597
• PEG Ratio: 0.06
• Price to Book (P/B): 1.61
• Price to Sales (P/S): 156.16
• P/FCF Ratio: -2.21
• Enterprise Value/Market Cap: -0.03
• Enterprise Value/Revenue: -2.22
• Enterprise Value/Gross Profit: -2.49
• Enterprise Value/Ebitda: 0.16
• 1Y Price Target: $9.00
• Price Target Upside: 26.23% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 53 Neutral
• Price Target: $6.00 ▼(-15.85% Downside)

CAMP4 Therapeutics Corporation's overall stock score reflects a challenging financial position with high leverage and negative profit margins, offset by strong technical momentum and positive corporate developments. The stock's valuation is unattractive due to a negative P/E ratio and lack of dividends. However, the initiation of GLP toxicology studies for a key product candidate provides a positive outlook for future growth potential.

Positive Factors

Innovative Product Development

The initiation of GLP toxicology studies for CMP-SYNGAP-01 marks a significant step towards clinical trials, showcasing CAMP4's commitment to addressing unmet medical needs in SYNGAP1-related disorders. This progress could enhance the company's long-term growth potential and strengthen its market position in RNA-based therapies.

Strategic Partnerships

CAMP4's strategic partnerships and licensing agreements provide crucial funding and resources for R&D, supporting sustainable growth. These collaborations can lead to milestone payments and royalties, enhancing revenue streams and reinforcing the company's position in the biotechnology sector.

High Gross Profit Margin

A high gross profit margin indicates efficient cost management and strong pricing power, which can support long-term profitability. This margin provides a buffer against operational inefficiencies and financial challenges, contributing to the company's potential for sustainable growth.

Negative Factors

High Leverage

High leverage poses significant risks, limiting financial flexibility and increasing vulnerability to economic downturns. This reliance on debt financing could strain cash flows and hinder the company's ability to invest in growth opportunities, impacting long-term stability.

Negative Cash Flow

Negative cash flow indicates challenges in sustaining operations and funding growth initiatives. Inefficient cash conversion and weak cash flow management raise concerns about liquidity, potentially affecting the company's ability to meet financial obligations and invest in future projects.

Declining Revenue

Declining revenue reflects instability in the company's core operations and market demand. This trend can undermine investor confidence and limit resources for R&D and expansion, challenging CAMP4's ability to maintain competitive advantages and achieve long-term growth.

CAMP4 Therapeutics Corporation Business Overview & Revenue Model

Company Description

CAMP4 Therapeutics Corporation (CAMP) is a biotechnology company focused on harnessing the power of RNA biology to develop transformative therapies for patients with serious diseases. The company operates primarily in the biotechnology sector, with a strong emphasis on leveraging its proprietary CAMP4 platform, which utilizes advanced computational and experimental techniques to identify and develop novel therapeutic candidates. CAMP's core products and services include therapeutic programs targeting genetic disorders and other diseases, with a focus on RNA-targeted therapies that aim to modulate gene expression and restore normal cellular function.

How the Company Makes Money

CAMP4 Therapeutics primarily generates revenue through several key streams, including research collaborations, licensing agreements, and potential milestone payments from partnerships with larger pharmaceutical companies. The company often enters into strategic partnerships to co-develop its therapeutic candidates, which can provide upfront payments and ongoing funding for research and development. Additionally, CAMP may receive royalties on sales of products developed from its proprietary technologies. The success of its revenue model is significantly bolstered by the strong demand for innovative treatments in the biotechnology sector and the increasing interest from investors and partners in RNA-based therapies.

CAMP4 Therapeutics Corporation Financial Statement Overview

Summary

CAMP4 Therapeutics Corporation faces significant financial challenges, with declining revenues, negative profit margins, and high leverage. The company's financial health is strained, with operational inefficiencies and cash flow issues. While there are some strengths, such as a high gross profit margin, the overall financial position is precarious, requiring strategic improvements to stabilize and grow the business.

Income Statement

CAMP4 Therapeutics Corporation has shown significant volatility in its revenue and profit margins. The company experienced a dramatic revenue decline from 2020 to 2024, with a notable drop in net profit margins, indicating challenges in maintaining profitability. The gross profit margin remains high, but negative EBIT and EBITDA margins highlight operational inefficiencies. The revenue growth rate is erratic, with periods of decline, suggesting instability in revenue streams.

Balance Sheet

The balance sheet reveals a concerning financial structure with fluctuating debt-to-equity ratios, reaching as high as 16.81 in 2023, indicating high leverage. The negative return on equity suggests that the company is not generating sufficient returns on shareholders' investments. The equity ratio is low, reflecting a reliance on debt financing, which could pose risks if not managed properly.

Cash Flow

CAMP4 Therapeutics Corporation's cash flow statement indicates negative operating and free cash flows, with inconsistent free cash flow growth. The operating cash flow to net income ratio is negative, suggesting inefficiencies in converting income into cash. The free cash flow to net income ratio is slightly positive, but overall cash flow management appears weak, raising concerns about liquidity and financial flexibility.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.80M	652.00K	350.00K	0.00	295.84M	308.59M
Gross Profit	3.39M	652.00K	350.00K	0.00	121.89M	122.41M
EBITDA	-53.58M	-51.39M	-50.20M	-44.12M	7.49M	18.13M
Net Income	-53.40M	-51.79M	-49.29M	-44.19M	-31.15M	-21.16M
Balance Sheet
Total Assets	86.39M	78.31M	54.95M	102.55M	402.29M	441.82M
Cash, Cash Equivalents and Short-Term Investments	75.25M	64.04M	38.38M	83.19M	91.11M	91.69M
Total Debt	6.35M	8.65M	11.69M	12.39M	209.17M	210.80M
Total Liabilities	27.73M	15.16M	178.68M	180.08M	322.11M	342.50M
Stockholders Equity	58.67M	63.14M	-123.73M	-77.53M	80.18M	99.32M
Cash Flow
Free Cash Flow	-47.68M	-46.00M	-44.83M	-42.57M	-17.52M	17.23M
Operating Cash Flow	-47.13M	-45.56M	-44.16M	-38.54M	-4.22M	28.59M
Investing Cash Flow	-785.00K	-441.00K	-678.00K	-4.03M	-7.58M	-13.69M
Financing Cash Flow	120.37M	71.66M	301.00K	100.16M	-2.64M	-27.32M

CAMP4 Therapeutics Corporation Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7.13
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CAMP, the sentiment is Positive. The current price of 7.13 is above the 20-day moving average (MA) of 4.40, above the 50-day MA of 4.04, and above the 200-day MA of 2.77, indicating a bullish trend. The MACD of 0.82 indicates Negative momentum. The RSI at 80.21 is Negative, neither overbought nor oversold. The STOCH value of 97.58 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CAMP.

CAMP4 Therapeutics Corporation Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CAMP	53 Neutral	$328.64M	-2.91	-172.70%	―	―	5.51%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ARTV	46 Neutral	$111.68M	-1.33	-47.96%	―	-100.00%	-17.10%
BYSI	44 Neutral	$81.42M	-4.77	―	―	―	―
RLMD	41 Neutral	$330.00M	-2.23	-196.79%	―	―	37.37%
INKT	38 Underperform	$56.14M	-3.86	―	―	―	21.48%
OSTX	27 Underperform	$57.05M	-1.89	-914.04%	―	―	-133.00%

CAMP4 Therapeutics Corporation Corporate Events

CAMP4 Initiates GLP Toxicology Studies for CMP-SYNGAP-01

On October 1, 2025, CAMP4 Therapeutics announced the initiation of GLP toxicology studies for its lead product candidate, CMP-SYNGAP-01, aimed at treating SYNGAP1-related disorders. The studies are a crucial step toward a clinical trial application, potentially leading to a Phase 1/2 clinical trial by the second half of 2026. SYNGAP1-related disorders, which significantly impact cognitive development, currently lack FDA-approved therapies, highlighting the potential impact of CAMP4’s innovative approach on the treatment landscape.